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Abstract: Kaposi’s sarcoma is a vascular tumor linked to the presence of  Kaposi’s 
sarcoma-associated herpesvirus (human herpesvirus-8) and the incidence of which has 
increased considerably the world over after the onset of the human immunodeficiency virus 
(HIV) pandemic. Antiretroviral therapy combined with cytotoxic agents has been established 
as the treatment of choice in the past 10 years. Among chemotherapeutic agents, pegylated 
liposomal doxorubicin has become the preferred one for patients with HIV-associated Kaposi’s 
sarcoma in Western countries. The drug in this formulation localizes better to the tumor and has 
higher efficacy. Skin toxicity, mucositis, and leukopenia/neutropenia are the main side effects. 
Hepatotoxicity and mild cardiotoxicity are observed less frequently. Pegylated liposomal 
doxorubicin impacts favorably on quality of life. Although cost effective in Western countries, 
the drug is less so in developing countries.
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Pegylated liposomal doxorubicin is the treatment of choice for serious cases of  Kaposi’s 
sarcoma in human immunodeficiency virus (HIV)-infected patients. Before reviewing 
its properties, results of clinical trials, indications, and side effects, we will review 
briefly the main features of Kaposi’s sarcoma in people with HIV-1 infection.
Kaposi’s sarcoma
Kaposi’s sarcoma (KS) is linked to the Kaposi’s sarcoma-associated herpesvirus 
(KSHV),1 also known as human herpesvirus-8 (HHV-8) and identified for the first 
time in 1994 from KS tissue samples.2 The virus is most closely homologous to the 
gamma-herpesvirus family,3 and has also been identified in samples from patients with 
primary effusion lymphoma and HIV-associated multicentric Castleman disease.4,5
Infection with KSHV appears to be necessary for the development of KS, but only 
a small proportion of KSHV-infected people ever develop the tumor. Although the risk 
of KS appearance increases significantly with declining immune function, as measured 
by CD4 T cell counts, the tumor can appear at any stage of HIV infection.6,7
As a result of the HIV epidemic, there has been a global increase in the incidence 
of KS. During the 1990s, a 20-fold increase was observed in African areas with a high 
co-occurrence of HIV and KSHV8,9 and the incidence has also increased in countries 
where KS was rare before the HIV epidemic.9 In spite of the impact of modern 
antiretrovirals that have considerably reduced its incidence, KS continues to be the 
most common neoplasm in patients with HIV-1 infection.Biologics: Targets & Therapy 2009:3 386
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HIV-associated KS presents with cutaneous lesions. 
Different degrees of lymphedema of variable size may occur, 
particularly in the lower extremities, genitalia, and face.10 
Extracutaneous spread is a common manifestation. Although 
any organ can be affected, including lymph nodes, liver, 
pancreas, heart, testes, bone marrow, spleen, heart and 
pericardium,11 KS mainly affects the oral cavity, palate, 
gingiva, gastrointestinal tract, larynx, and lungs.12–14
The clinical course of HIV-associated KS can be minimal 
or aggressive and even fulminant.15 If untreated, the disease 
is usually progressive and only rarely and temporarily 
spontaneous regressions can occur.16
Pegylated liposomal doxorubicin
Pharmacology
Polyethylene glycol (PEG) liposomal doxorubicin is a 
formulation of doxorubicin in which the drug is encapsulated 
in PEG-coated liposomes. It differs greatly from the free 
drug in pharmacokinetics, toxicity profile, and therapeutic 
values. It consists of a liquid suspension of liposomes 
(vesicles with an approximate mean diameter in the range 
of  80–90 nm) composed of a lipid bilayer membrane 
made up of hydrogenated soy phosphatidylcholine and 
cholesterol. Doxorubicin, which is a cytotoxic antibiotic, is 
an anthracycline contained in the internal aqueous compart-
ment of the liposome.17 Each individual liposome contains 
10,000–15,000 molecules.18,19 The liposome surface is coated 
with a PEG polymer layer. This hydrophobic coating protects 
the liposome from opsonization and rapid reticuloendothelial 
system-mediated clearance.20
The antitumor activity of doxorubicin can be mainly 
explained through the inhibition of DNA synthesis. 
Doxorubicin, lodging between adjacent DNA base pairs, 
deforms and fragments the DNA, causing cell death.17,21–23
The drug also acts indirectly through the activity of free 
radicals, which are formed during its metabolization and 
can cause damage to mitochondrial, cellular, and nuclear 
membranes, sarcoplasmic reticulum, DNA, and various other 
intracellular components.24
The antitumor activity of doxorubicin may also be due 
to its ability to increase the numbers of phagocytic cells in 
KS lesions.25
The pharmacokinetic profile of  PEG liposomal doxorubicin 
is linear over a dose range of 10 to 20 mg/m2, while an increase 
in dose to 50 mg/m2 is associated with a nonlinear profile.26
The AUC for doxorubicin is large and equal to 564 and 
902 mg per h/L, after administration of PEG liposomal 
doxorubicin 20 and 50 mg/m2, respectively.26
The prolonged circulation time allows PEG liposomal 
doxorubicin to preferentially accumulate in tumor tissue. 
The liposomes, once trapped in the tumor interstitial fluid, 
slowly release doxorubicin. Most of doxorubicin that circu-
lates in plasma is encapsulated in liposomes, whereas very 
little doxorubicin circulates as free drug.
After PEG liposomal doxorubicin administration, the 
drug accumulates in KS tissues and its concentrations are 
about 10 to 20 times higher than in normal tissues.26
Bile is the major route of doxorubicin excretion. 
Doxorubicin metabolites are detected at low concentrations in 
urines, and are not detected or detected in low concentrations 
in plasma.26
Efficacy
Initially, two phase II studies indicated that pegylated 
liposomal doxorubicin was a highly potent and well-tolerated 
agent in acquired immunodeficiency syndrome (AIDS)-
related KS when relatively low doses (20 mg/m2) were 
used every three weeks (Table 1).27,28
Subsequently, two phase III studies compared pegylated 
liposomal doxorubicin to adriamycin–bleomycin–vincristine 
(ABV), and bleomycin–vincristine (BV), two of the most 
common regimens used to treat KS, and found that PEG 
liposomal doxorubicin was significantly more effective than 
the previously used standard regimens.29,30
Pegylated liposomal doxorubicin was also found to have 
antitumor activity against KS patients who experienced 
disease progression during ABV chemotherapy.31
The Caelyx/KS Spanish Study Group was a randomized, 
open-label, multicenter study where HIV-infected patients 
with KS were randomly selected to receive highly active 
antiretroviral therapy (HAART) plus pegylated liposomal 
doxorubicin from the beginning of the study (group A) or 
to receive HAART alone (group B).32 The inclusion criteria 
were adult HIV–KS-affected patients (biopsy confirmed) 
with positive HIV-RNA because they were naïve, or not on 
HAART, or failing treatment. Patients had to have at least 
10 cutaneous lesions or mucosal or visceral involvement to 
be included. Patients with life-threatening KS were excluded. 
Intravenous PEG liposomal doxorubicin was administered at 
doses of 20 mg/m2 every three weeks. The total number of 
cycles was decided by each investigator. Patients in group B 
who had KS progression or did not respond to HAART alone 
were considered as nonresponders and allowed to receive 
pegylated liposomal doxorubicin. Twenty-eight patients 
were included in the study (13 in group A, 15 in group B). 
Overall five patients had visceral involvement (three with Biologics: Targets & Therapy 2009:3 387
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lung and two with gastric disease). Complete or partial 
remission in intent-to-treat analysis was 76% versus 20% for 
groups A and B, respectively, and in on-treatment analysis, 
91% versus 23%, respectively. Ten patients in group B had 
to be rescued with PEG liposomal doxorubicin.32 The only 
factor related to response in multivariate logistic regression 
analysis was the use of pegylated liposomal doxorubicin. The 
median number of cycles received was 11. This study showed 
a good response rate (76%) and tolerance of the combination 
of HAART plus PEG liposomal doxorubicin.32
The German Clinical AIDS Working Group did an 
uncontrolled, observational trial in 54 patients with a 
confirmed HIV-1 infection and a proven diagnosis of KS 
receiving different HAART regimens (two nucleoside 
reverse transcriptase inhibitors in combination with either 
1–2 protease inhibitors or one nonnucleoside reverse 
transcriptase inhibitor or abacavir) and sequentially included 
into the study at five different treatment centers from 
1997–2002.33 Patients with all stages of KS were eligible 
for study participation, and visceral involvement was present 
in 29.6%. Exclusion criteria were bone marrow depression, 
renal or hepatic damage, active opportunistic infection, and 
Karnofsky performance index 50%. Pegylated liposomal 
doxorubicin was administered intravenously at a dosage of 
20 mg/m2 every two weeks. The patients received a median of 
14 cycles of chemotherapy. Overall, 81.5% of study patients 
developed a response to the combined treatment, with a 
total of 55.5% and 26% of individuals reaching partial or 
complete responses, respectively.33 After the completion of 
chemotherapy, 81.5% of the patients sustained their treatment 
responses for more than one year. The treatment outcomes 
of this study were superior to studies that used liposomal 
doxorubicin without additional antiretroviral combination 
therapy, where mostly unsustained treatment responses were 
obtained in 25%–80% of patients.30,34,35
In this study the patients treated with PEG liposomal 
doxorubicin and HAART maintained stable levels of absolute 
CD4+ T cell counts while increasing relative CD4+ T cell 
numbers, and additional opportunistic infections did not 
occur during the entire study period.33 This observation was in 
sharp contrast with the high incidences of opportunistic 
infections in patients receiving liposomal doxorubicin in the 
pre-HAART era, when patients’ HIV-1-associated suscepti-
bility to opportunistic infections was potentiated by recurrent 
episodes of chemotherapy-related leucopenia.
One prospective, double-blind, multicenter (seven sites), 
active control study published in 2007 randomized patients 
with KS to six cycles of pegylated liposomal doxorubicin 
(20 mg/m2, 60 patients) or liposomal daunorubicin (40 mg/m2, 
19 patients) every two weeks.36 Clinical benefit was observed 
in 80% of patients receiving pegylated liposomal doxorubicin 
and in 63.2% of those receiving liposomal daunorubicin. 
Benefit was maintained for a median of 62 days in PEG 
liposomal doxorubicin-treated patients and for a median 
of 55 days in those treated with liposomal daunorubicin.36 
Tumor responses were achieved by 55% of patients receiving 
Table 1 Summary of trials of pegylated liposomal doxorubicin in patients with HiV-related Kaposi’s sarcoma.   The drug was administered 
intravenously once during each cycle
Reference  
(Author, study design)
Patients  
no.
Dosage regimen  
(no. of cycles)
HAART  Response  
rate
Median duration of 
response (weeks)
27 (Simpson, open label) 16 20 mg/m2 every  
2–3 weeks (1–3)
No 68.7 14
28 (Harrison, open label) 34 20 mg/m2 every  
three weeks (2–4)
No 73.5 9
29 (Northfelt, randomized, 
nonblind, multicenter)
133 20 mg/m2 every  
two weeks (6)
No 45.9 13
30 (Stewart, randomized, 
nonblind, multicenter)
121 20 mg/m2 every  
three weeks (6)
No 58.7 20
32 (Martın-Carbonero, 
randomized, open-label, 
multicenter)
13 20 mg/m2 every  
three weeks (7–14)
Yes 76.0 Not reported
33 (Lichterfeld, uncontrolled, 
observational)
54 20 mg/m2 every  
two weeks (10–100)
Yes 81.5 52
36 (Cooley, prospective, 
randomized, double-blind, 
multicenter)
60 20 mg/m2 every  
two weeks (6)
Yes 55.0 22
Abbreviation: HAArT,  highly active antiretroviral therapy.Biologics: Targets & Therapy 2009:3 388
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PEG liposomal doxorubicin and 31.6% of those treated with 
liposomal daunorubicin.36
A recent trial evaluated 36 patients with AIDS-associated 
KS  requiring  chemotherapy  who  were  treated  for 
six three-week cycles of pegylated liposomal doxorubicin at 
usual doses (20 mg/m2) plus interleukin-12 (IL-12; 300 ng/kg 
subcutaneously twice weekly), followed by 500 ng/kg sub-
cutaneous IL-12 twice weekly for up to three years.37 All 
patients also received HAART. Twenty-two patients had 
poor-prognosis KS (T1S1 stage).37 Thirty of 36 patients had a 
major response (including nine with complete response) and 
responses were sustained on IL-12 maintenance therapy.37
Finally, one retrospective analysis of all patients who 
had received pegylated liposomal doxorubicin in centers 
belonging to the Caeylix/KS Spanish group study evaluated 
the long-term efficacy of the drug combined with HAART in 
preventing KS relapse.38 A total of 98 HIV-infected patients 
with KS who had received PEG liposomal doxorubicin 
as part of two clinical trials32,39 were evaluated. Of the 
75 patients with complete or partial response to initial 
PEG liposomal doxorubicin, 61 had data included in the 
study from a control visit after completion of therapy. In a 
median follow-up of 50 months, eight patients (13%) had 
experienced relapse, five of whom within the first year after 
stopping chemotherapy.38 Hence the overall rate of relapse 
among patients who responded to therapy was 13.5% per 
year, with most relapses occurring within the first year after 
therapy was discontinued.
Toxicity
Skin toxicity, in the form of palmar-plantar erythrodysesthesia 
(also known as acral erythema or hand-foot syndrome), and 
mucositis are the two major dose-limiting toxicities of 
pegylated liposomal doxorubicin, but are rarely observed at 
the doses used for KS, as they have been described in patients 
with other tumors treated with higher doses (50 mg/m2 every 
four weeks).
PEG liposomal doxorubicin has a mild myelosuppressive 
effect characterized mainly by leukopenia/neutropenia. The 
white blood cell count nadir is usually detected 2–3 weeks 
after infusion. Neutropenia-related fever is very rare.
A cardiac biopsy study in 10 patients with KS treated 
with cumulative doses of 440–900 mg/m2 reported a near-
normal endomyocardial biopsy score with a median of  0.3 
on a seven-point scale previously described by Billingham 
and colleagues,40 a score 10 times lower than that for matched 
historical controls receiving similar cumulative doses of 
doxorubicin.41
In the Caelyx/KS Spanish Study Group, one or more 
adverse events were identified in 33% of the patients, the 
most common being anemia and neutropenia, followed by 
mucositis, enteritis, hepatotoxicity, and fever.32 There were 
two deaths during treatment with PEG liposomal doxorubicin, 
unrelated to therapy or KS.32 In the German Clinical AIDS 
Working Group study, although hematological adverse events 
(especially leucopenia) were the most frequent side effects, 
severe (World Health Organization stage IV) hematological 
adverse reactions were seen in only two individuals.33 
Hepatotoxicity and mild cardiotoxicity were the other side 
effects observed. Six patients died within eight months of 
the study completion: one died of KS, and the remaining five 
of causes that were not mentioned.33
In the study comparing pegylated liposomal doxorubicin 
with liposomal daunorubicin, adverse events associated with 
PEG liposomal doxorubicin were neutropenia (30%), nausea 
(28.3%), and asthenia (16.7%).36 No change in median LVEF 
was observed over the course of the study.36
Quality of life
The effect of pegylated liposomal doxorubicin compared with 
doxorubicin-bleomycin-vincristine on health-related quality 
of life was assessed in one randomized study.42 From baseline 
to the end of treatment (21 days after the last chemotherapy 
cycle) patients receiving PEG liposomal doxorubicin 
improved significantly in pain, cognitive functioning, social 
functioning and health distress, whereas patients receiving 
doxorubicin-bleomycin-vincristine deteriorated significantly 
in energy/fatigue.42
Cost-effectiveness
In two initial economic analyses comparing chemotherapy 
regimens for KS that considered the European and American 
conditions, the cost-effectiveness results (defined as average 
cost per responder) favored pegylated liposomal doxorubicin 
when compared to liposomal daunorubicin or to combination 
chemotherapy.43,44
A more recent study from Brazil confirmed that, even 
though PEG liposomal doxorubicin has a higher acquisition 
cost compared to liposomal daunorubicin, when the average 
cost per responder is considered pegylated liposomal doxo-
rubicin has a better cost-effectiveness profile.45 However, 
at difference with previous reports, this latter study showed 
that the doxorubicin-bleomycin-vincristine regimen, which 
is no longer considered the first choice, was the most rational 
treatment option in a resource-limited country like Brazil.45 
Indeed the incremental cost per additional responder of using Biologics: Targets & Therapy 2009:3 389
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PEG liposomal doxorubicin instead of ABV was as high 
as US$20,990.45
Long term consequences of treatment
In the retrospective analysis conducted by Caeylix/KS 
Spanish group, 29 out of 98 patients (30%) died during a 
median follow up period of 28.7 months.38 Eight patients 
died while receiving PEG liposomal doxorubicin cycles, 
nine died during the first year after stopping chemotherapy, 
twelve died 11 years after completion of therapy.38 In nine 
patients the cause of death was related to the appearance of 
other tumors (seven lymphomas, one gastrointestinal adeno-
carcinoma, one tongue epidermoid cancer).38 Death caused 
by progression of KS occurred in three cases. The rate of 
non-Hodgkin’s lymphoma in this series was high (2.3% per 
year).38 Overall, the mortality rate was 14.6% per year.
The observation that the number of PEG liposomal 
doxorubicin treatment cycles was not associated with 
morbidity or mortality seems to be against the idea that the 
drug was linked to either. It should also be noted that an 
increasing risk of non-Hodgkin’s lymphoma among patients 
with KS is observed even in HIV-negative individuals,46 and 
three of the cases observed in the Caelyx/KS Spanish Study 
Group study were primary effusion lymphoma,38 likely linked 
to HHV-8 similarly to KS.
Conclusions
Treatment of  KS in HIV-infected patients has been considerably 
improved by the use of modern antiretrovirals, which represent 
the cornerstones of therapy. Pegylated liposomal doxorubicin 
appears to be the best added treatment available for those 
cases with life-threatening KS or extensive disease com-
promising an organ function.47 Response to therapy must be 
evaluated carefully and regularly to prevent excessive dosages 
of chemotherapy and long term negative consequences.
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